Media Room
Joe Hernandez, CEO, Signal Genetics, and Dr Yves Fradet, President of DiagnoCure Inc.
New collaboration with Signal Genetics
June 29, 2011
New Collaboration with Signal Genetics, valued at US$ 13.3M, for the commercialization of PrevistageTM GCC
New publication on GCC's prognostic value
May 6, 2011
New Study: the PCA3 test could be useful to predict the outcome of an initial prostate biopsy
April 22, 2010
Video
Corporate Information
Logos
- DiagnoCure – Color (PNG)
- DiagnoCure – Black & White (PNG)
Contact
Geneviève Couture
Coordonator, Administration and Communication
(418) 527-6100
communications@diagnocure.com